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Changes in the nature and structure of healthcare pathways have implications for healthcare 3 
professionals’ jurisdictional boundaries. The introduction of treatment focused BRCA1 and 2 4 
genetic testing (TFGT) for newly diagnosed patients with breast cancer offers a contemporary 5 
example of pathway change brought about by technological advancements in gene testing and 6 
clinical evidence, and reflects the cultural shift towards genomics. Forming part of an 7 
ethnographically informed study of patient and practitioner experiences of TFGT at a UK 8 
teaching hospital, this paper focuses on the impact of a proposal to pilot a mainstreamed TFGT 9 
pathway on healthcare professionals’ negotiations of professional jurisdiction. Based upon semi-10 
structured interviews (n=19) with breast surgeons, medical oncologists and members of the 11 
genetics team, alongside observations of breast multidisciplinary team meetings, during the time 12 
leading up to the implementation of the pilot, we describe how clinicians responded to the 13 
anticipated changes associated with mainstreaming. Interviews suggest that mainstreaming the 14 
breast cancer pathway, and the associated jurisdictional reconfigurations, had advocates as well as 15 
detractors. Medical oncologists championed the plans, viewing this adaptation in care provision 16 
and their professional role as a logical next step. Breast surgeons, however, regarded 17 
mainstreaming as an unfeasible expansion of their workload and questioned the relevance of 18 
TFGT to their clinical practice. The genetics team, who introduced the pilot, appeared cautiously 19 
optimistic about the potential changes. Drawing on sociological understandings of the 20 
negotiation of professional jurisdictions our work contributes a timely, micro-level examination 21 
of the responses among clinicians as they worked to renegotiate professional boundaries in 22 
response to the innovative application of treatment-focused BRCA testing in cancer care – a 23 



















Care pathways are locally developed guidelines which outline the order and timing of healthcare 29 
that patients receive and the roles and responsibilities of practitioners involved in care provision. 30 
These infrastructural technologies came to prominence in the 1980s in North America (Allen 31 
2009, 2014) and are now firmly established within modern healthcare (Martin et al. 2017).  The 32 
potential cost-saving and standardising effects of the introduction of care pathways into 33 
healthcare have been widely acknowledged (Martin et al. 2017; Hunter and Segrott 2008; Berg et 34 
al. 2000). But while efforts to standardise and promote transparency of practice fit within the 35 
contemporary ‘audit culture’ (Strathern 2000), it is recognised that the introduction of care 36 
pathways might also create tensions. Casting a critical eye over the care pathway movement, 37 
Pinder et al. (2005) note that while the introduction of care pathways might be built upon good 38 
intentions and the ideal of rationalised planning, this organisational map making can have 39 
negative consequences, not least in relation to healthcare professionals’ perceptions of 40 
professional autonomy, and inter-professional jurisdictional boundary negotiations.  41 
Care pathways and the sociology of professions  42 
Abbott’s (1988) work on the social nature of workplace relationships and professional control 43 
offers a useful analytical foundation for examination of the fluidity of professional workplace 44 
jurisdictions in relation to care pathway development. Elucidating the concept of workplace 45 
jurisdiction, Abbott (1988) notes that far from being fixed, a profession’s control, or ownership, 46 
of tasks is open to continuous, competitive negotiation. Abbott’s work is, however, concerned 47 















time  under  internal  or  external  pressure’ (Timmermans 2002: 552) and has been criticised for 49 
over-simplifying the complexity of workplace jurisdictional negotiations (Macdonald 1995).  50 
Sociologically-informed studies examining the impact of workforce change within the NHS in 51 
relation to jurisdictional defence and negotiation are numerous, and highlight the mobilisation of 52 
occupational legitimacy discourses used by different occupational groups to assert new or 53 
established professional jurisdiction in relation to others (Sanders and Harrison 2008; Hunter 54 
and Segrott 2008; Nancarrow and Borthwick 2005; Timmons and Tanner 2004; Allen 1997). As 55 
Timmons and Tanner (2004) note, examples of boundary disputes include those involving 56 
hierarchical jurisdictional negotiations, as well as those conducted among professions with a 57 
similar status.   58 
While it is suggested that the changes that come with care pathway development can improve 59 
inter- professional collaboration and cooperation (Harvey and Currie 2000), they can also be 60 
counterproductive, as healthcare professionals react by ‘protecting, expanding or closing ranks’ 61 
around their jurisdictional territory (Huby et al 2014). An example of this is seen in the 62 
emergence of new professional roles and the enactment of a form of legitimising discourse, used 63 
by professionals – new and old – to try and assert their (new/established) professional 64 
jurisdiction in relation to others. For example, Timmons and Tanner investigated the highly 65 
charged occupational boundary dispute between theatre nurses and new ‘Operating Department 66 
Practitioners’. They reported on the demarcation disputes that ensued following the introduction  67 
of new professionals (ODPs), and how both groups – the nurses and ODPs – deployed a range 68 
of rhetorical strategies in order to defend what they viewed as their jurisdictional territory 69 
(Timmons and Tanner 2004).  70 
Jurisdictional conflict is not only the result of the introduction of new roles into the NHS, but 71 
can also emerge as a result of the implementation of new technologies, which may cause a 72 















occupational division of labour between gastroenterologists and surgeons in response to the 74 
development of gastrointestinal endoscopy, Zetka suggests that the introduction of endoscopy 75 
blurred the ‘traditional lines of demarcation’ (2001:1507) and triggered conflict between 76 
gastroenterologists and surgeons, as the groups vied for control over the technology. But, while 77 
much of the existing literature on the sociology of professions details inter- or intra-professional 78 
conflict occurring as a result of new possibilities of practice – either the emergence of new roles 79 
or the introduction of innovative technologies - there remains relatively little attention paid to 80 
the impact of innovative genetic technologies on professional jurisdictional negotiations, which 81 
seems surprising given the hype and hope that has surrounded this technology since the turn of 82 
the century.  83 
Care pathways, professional jurisdictions and genetic technologies   84 
In their qualitative study of the provision of cancer genetic services for hereditary cancer 85 
syndromes in Ontario, Canada, Miller et al. (2008) speak of the co-evolution of two parallel 86 
professional communities of practice that have emerged in the context of the growing influence 87 
of genetics in medicine. Members of these two communities, (genetic counsellors, family 88 
physicians, non-genetics physicians such as surgeons, and general practitioners), spoke of either a 89 
‘genetic vision’ of cancer care or, an ‘oncogenetic vision’.  The genetic vision represented a future 90 
characterised by the devolution of day-to-day tasks to other specialists while simultaneously 91 
protecting the sovereignty of genetics expertise. Conversely, the oncogenetic vision saw genetic 92 
testing as cancer prevention, informing management and treatment and, as such, positioned 93 
genetic expertise as ‘a supportive element in the core cancer service’ (Miller et al. 2008: 158). 94 
Miller et al. (2008) note that, in contrast to much of the literature on negotiations of professional 95 
jurisdiction, their study is not so much an account of professions in conflict, but rather a 96 
demonstration of how heterogeneous communities of practice can emerge in response to the 97 















Two further studies (Martin et al. 2009; Robins and Metcalfe, 2004) focus on the impact of the 99 
integration of genetic technologies into primary care. Discussing the role of general practitioners 100 
with specialist interest (hereafter GPSI) in relation to specialist colleagues in tertiary care, Martin 101 
et al. (2009) examined how the division of labour between clinical genetics and GPSIs was 102 
negotiated at several pilot sites. The study highlighted that both cooperative and less constructive 103 
relationships were formed between GPSIs and clinical geneticists and that, while the former were 104 
keen to demonstrate their competence in genetic knowledge, the clinical geneticists claimed that 105 
only day-to-day immersion in the knowledge field would result in true expertise. In contrast, 106 
Robins and Metcalfe’s (2004) Australian study focused on the integration of genetics into 107 
primary care practices, and found that GPs held ambivalent views, claiming a lack of 108 
understanding of genetics, coupled with uncertainty as to the relevance of genetic testing to 109 
patient management.  110 
Each of these studies teased out central questions about the negotiation of control of genetic 111 
technologies among healthcare professionals and highlighted central themes in participant 112 
narratives linked to perceptions of expertise and clinical relevance. These themes also came up in 113 
our own work as we examined the professional jurisdictional negotiations that were triggered by 114 
the proposal to mainstream the pathway for the delivery of ‘treatment-focused’ BRCA1 and 2 115 
genetic testing (hereafter TFGT) for newly diagnosed breast cancer patients in oncology. 116 
Bringing together the views of surgeons, medical oncologists and genetics team members as they 117 
prepared for the mainstream pilot, our study contributes new insights into how innovative 118 
applications of existing BRCA testing technology influenced occupational divisions of labour as 119 
this group of professional contemplated incorporating genetic testing in their clinical practice.  120 
A note on ‘treatment-focused genetic testing’ for BRCA1 and BRCA2 gene mutations  121 
Dominantly inherited BRCA1 and BRCA2 gene mutations are known to be associated with 122 















to technological advances in, and decreasing costs of, gene sequencing in recent years (Trainer et 124 
al. 2010), and new evidence from clinical trials of targeted treatments in BRCA mutation positive 125 
women (George et al. 2017), BRCA testing has expanded from its predictive and diagnostic 126 
functions to inform personalised cancer treatment plans (NICE 2013). TFGT has the goal of 127 
stratifying patients according to their BRCA mutation status and targeting their treatment as a 128 
result. This recent application of BRCA testing offers patients streamlined treatment pathways, 129 
particularly where TFGT is offered by cancer specialists (surgeons or medical oncologists) within 130 
mainstream cancer care. 131 
 132 
METHODS 133 
Data collection 134 
Findings presented herein originate from a larger, ethnographically-informed study of patient 135 
and practitioner experiences of TFGT at one UK teaching hospital, which sought to examine 136 
individuals’ experiences of the shift towards the mainstreaming of genetics into routine cancer 137 
care.  In their introduction to a special collection on hospital ethnography van der Geest and 138 
Finkler note that  ‘possibilities for anthropological research in hospitals vary’, (2004: 1999) due to 139 
differing cultural norms of privacy and patient well-being – concerns which are managed through 140 
ethical review boards. We use the term ‘ethnographically-informed’ to describe our research in 141 
order to indicate the adaptation of traditional ethnographic methods, specifically, participant 142 
observation that we undertook in this study. Our observations were structured and limited to 143 
certain spaces and, as such, offer an example of Wind’s reworking of participant observations as 144 
‘negotiated interactive observations’: ‘what happens when you are doing fieldwork without at the 145 
same time assuming that you become one of “them”’ (2008: 87).  In this paper, we focus 146 
exclusively on data from the breast cancer care pathway, at a time when it was preparing to pilot 147 















period of negotiation and early implementation of the new pathway, our findings report the 149 
anticipatory views of those working in breast cancer care.  150 
Fieldwork was conducted by SW in 2017 and involved twice-weekly attendance at the breast 151 
multidisciplinary meetings (MDM) over a six-month period, with most meetings lasting between 152 
2-3 hours. Despite being structured and limited to the MDM, observations allowed SW to 153 
examine the processes of patient triage and inter-professional communication pertaining to the 154 
proposed mainstream pathway. Furthermore, observations allowed SW to become known to the 155 
clinicians enabling the successful recruitment of practitioners to the study. Nineteen semi-156 
structured interviews were conducted with clinicians involved in breast cancer care. Participants 157 
were identified through contact with key clinical gatekeepers (in surgery and the genetics team). 158 
SW emailed potential participants an invitation, information sheet, and expression of interest 159 
form. Interview participants included six Breast Surgeons and a breast care nurse specialist (BS1-160 
7) who were responsible for triaging patients for onward referral to the genetics team, six 161 
Medical Oncologists (MO1-6) who were about to undergo training and start offering TFGT to 162 
breast cancer patients, and six members of the Clinical Genetics team (CG1-6) who currently 163 
offer TFGT to all breast patients fitting referral criteria. All interviews were digitally recorded. 164 
The University of Edinburgh Research Ethics Committee granted ethical approval.   165 
Data Analysis  166 
We conducted a thematic analysis of fieldwork materials (transcripts and field-notes). We first 167 
familiarised ourselves with the data, listening to audio files and reviewing our transcripts and 168 
field-notes (Pope, Ziebland and Mays 2000). SW and NH discussed emerging ideas and themes 169 
at regular meetings before independently coding the transcripts using NVivo11 software (QSR 170 
International Pty Ltd., 2015). Codes, and subsequent categories, were inductively and deductively 171 
determined (Maxwell 2012), that is, we were influenced both by a priori research questions (for 172 















recognition of new insights (for example, learning of the plans to mainstream the breast care 174 
pathway). While consideration of occupational boundaries was not the initial focus of our study, 175 
it nevertheless became a strong thread in our participant narratives, as they spoke of the plan to 176 
mainstream the breast care pathway.  177 
FINDINGS 178 
Figure 1 about here 179 
 180 
TFGT and the renegotiation of professional jurisdictional boundaries in the context of 181 
breast cancer care  182 
When we commenced this research, patients with breast cancer were offered TFGT in a 183 
standard care pathway. This meant that patients were triaged by their surgeons during their first 184 
appointment in order to determine whether they TFGT was appropriate. Triaging criteria 185 
included: age, family history (if known) and tumour type. Eligible patients were referred to 186 
clinical genetics where they received (expedited) pre-test counselling and BRCA testing, which 187 
commonly would comprise of a 45 minute counselling session, followed by a blood test, 188 
performed by the genetic counsellor. The genetic counsellor would then be responsible for 189 
sending the blood sample to the hospital laboratory, from where it would be sent on to the 190 
national laboratory for processing. Results of the test would then be returned to the genetics 191 
team. Only those identified as carrying a pathogenic mutation or Variant of Uncertain 192 
Significance (VUS) – a result which necessitates the interpretation of complex results - would be 193 
invited back to the genetics clinic to discuss their result and initiate a familial cascade. The timing 194 
of TFGT in relation to treatment varied between patients, depending on whether they had neo-195 















This standard pathway, based upon triage and, where appropriate, onward referral to clinical 197 
genetics for testing, established and reified ‘occupational jurisdictions’ (Hunter and Segrott 2014) 198 
- the roles and responsibilities of surgeons, medical oncologists and the genetics team in their 199 
daily practice. As one of the genetics team members said:  200 
‘Our role really is to go through the testing so that they can understand the implications of being tested 201 
and the possible outcomes… We have to very much take into consideration that this test result can 202 
impact the family and this is one of the things that I feel is really important so that they know that 203 
having a genetic test result can mean that their condition, their diagnosis can maybe effect other family 204 
members and other family members will be able to be tested and other family members might be at risk’ 205 
(CG1).   206 
While the genetics team were concerned with, both, the individual patient and their family 207 
members, the medical oncologists and surgeons, in contrast, described themselves as primarily 208 
focused on treating individual patients: 209 
[The oncologists’] area of work is personalised medicine and, hence, their focus is on individualised care. 210 
It should not be about treating of a disease but, rather, it is about treating a patient (notes from 211 
interview with MO2).  212 
‘We don’t say too much about the, you know, the implications for the other family because, you know, 213 
we’re here to treat cancer’ (BS6). 214 
During our research the clinical genetics team actioned a plan to pilot a mainstreamed pathway at 215 
the hospital; this entailed shifting the responsibility for consenting and BRCA testing from the 216 
genetics team to the surgeons and medical oncologists at the breast unit. This stage of ‘process-217 
mapping’, that is, deciding what should happen and when in the new pathway (Harvey and 218 
Currie 2000), demanded renegotiation of professional jurisdictions, as the genetics team sought 219 















and implementation of the pathway was achieved through adaptation of the Royal Marsden’s 221 
‘mainstreaming cancer genetics project’ to the local context, a job which was taken on by 222 
members of the genetics team. While this was an innovation, it was not the first time that the 223 
genetics team had introduced a mainstreamed approach to TFGT at the study site, as the ovarian 224 
cancer care pathway had been mainstreamed several years prior to our fieldwork. However, 225 
unlike the ovarian pathway, which delegated consenting and testing, and the interpretation and 226 
sharing of results with patients, the proposed breast pathway would see the genetics team 227 
maintaining jurisdiction over results interpretation and informing patients of their BRCA status.  228 
Contracting work boundaries: the clinical genetics team’s views on mainstreaming 229 
The introduction of TFGT had had profound implications for the genetics team, as the 230 
incorporation of this technology into their practice had meant that their workload had increased 231 
in recent years to a point where the service was struggling to cope. As a consequence, the 232 
genetics team were actively encouraging other professionals to share some of the workload 233 
associated with TFGT – an example of what Nancarrow and Borthwick (2005) refer to as 234 
‘horizontal substitution’, which is advantageous when services are at capacity. The proposal to 235 
relinquish taking consent for  genetic testing in this instance  was justified by some genetics team 236 
members as related to the indistinctness of professional responsibilities when it came to TFGT, 237 
as CG3 said ‘[just] because a patient has a genetic cancer doesn’t mean that they only belong to 238 
genetics: they have cancer, they need their treatment’. As Miller et al. (2008) found in their study 239 
of those involved in genetic cancer care in Ontario, there was a sense among some practitioners 240 
that the mainstreaming of cancer care was the future, and that the genetics clinic was not 241 
necessarily the right place for this care provision. Indeed, as CG3’s comment highlights, there 242 
was unresolved tension raised by TFGT, primarily because there was uncertainty about where 243 















Role diversification, or the adoption of a new role by a professional group (Nancarrow and 245 
Borthwick 2005), - in this case the surgeons/medical oncologists adopting the role of consent 246 
taker - was regarded by the genetics team as a means to divest themselves of a task so that they 247 
could refocus their attention on the familial implications of testing: 248 
 ‘I think the genetic counselling role obviously is of high importance when we’re looking at family and I 249 
don’t feel that’s going to go I think that’s always going to be the most important thing dealing with the 250 
management of the family’ (CG2).  251 
As noted above, the importance of looking beyond the individual and considering the family 252 
distinguishes the role of clinical genetics from that of other professionals in the breast cancer 253 
pathway. Indeed, the expertise of clinical genetics extends beyond the patient and the pathology, 254 
linking patient and kin through a relationship of risk (Hallowell 1999). Crucially, this sense of 255 
professional jurisdiction extending beyond the individual patient to their family offered a 256 
justification for why the genetics team appeared to be advocating for mainstreaming TFGT.  257 
‘We weren’t set up for it, they’re [genetic counsellors] on their knees, it will return us to actually being able to 258 
do our own job properly. I don’t think it takes away the role or anything, I think there’s all the pre-259 
symptomatic testing, which is what we’re really supposed to be about’ (CG4). 260 
As CG4 observed, mainstreaming this service would allow the clinical genetics team to return to 261 
their primary role of counselling and supporting those patients, specifically, those identified as 262 
mutation positive or as carrying VUS. In addition, the genetics team would be able to focus on 263 
not only the patients, but also the tasks of identifying and supporting family members 264 
undergoing pre-symptomatic testing.  265 
In summary, the proposal to mainstream TFGT potentially narrows the jurisdiction of the 266 
genetics team, allowing them to re-establish the boundaries around their specialist jurisdiction, 267 















jurisdictions, as they assume responsibility for offering TFGT and consenting patients. In the 269 
following section we consider how these non-genetic specialists responded to the possibility of a 270 
mainstreamed pathway, in relation to their workload, realms of expertise and perceptions of 271 
relevance of TFGT to clinical practice.  272 
Expanding work boundaries: Breast oncologists’ and surgeons’ reactions to 273 
jurisdictional renegotiations 274 
Our findings indicate that breast surgeons and medical oncologists had differing opinions about 275 
the implementation of a mainstream pathway. The medical oncologists who participated in our 276 
study appeared keen to complete the online training provided to them by the genetics team, so 277 
that they could start integrating the consenting of patients into their clinical practice. The reasons 278 
that medical oncologists gave for their enthusiasm for participating in the mainstream pathway 279 
included: their belief in their ability to take on this work, both in terms of expertise and 280 
workload, their understandings of the clinical relevance of TFGT and, finally, their sense that 281 
they were better suited to the task than their surgical colleagues. Primarily, the medical 282 
oncologists recognised that they had a number of skills - namely, discussing risks and benefits in 283 
oncology- that would suit the task of consenting patients for TFGT:  284 
‘I don’t feel uncomfortable in discussing it in broad terms, so in terms of consenting the patient…I don’t 285 
feel uncomfortable about that. I mean we have a lot of similar type of discussions, around other aspects of 286 
oncological care that are also… a question of balancing unquantified risks and unquantified benefits, or 287 
risks and benefits that haven’t got precise measures. So I think I can consent people meaningfully for the 288 
genetics test, which is probably the key question as to whether it’s right to mainstream or not’ (MO3).   289 
The experience of communicating uncertainty about treatment and prognosis to patients meant 290 
the medical oncologists viewed consenting patients for TFGT as falling well within their 291 
professional jurisdiction. This finding echoes Miller et al. who found that those  healthcare 292 















under the purview of genetic professionals as a ‘natural extension of their work’ (2008: 158). 294 
Furthermore, we found that some medical oncologists felt that offering TFGT was a more 295 
appropriate task for them than their surgical colleagues:  296 
‘You need this operation, these are the risks”. When it comes to discussing chemotherapy, and say 297 
adjuvant chemotherapy, it’s really common that we have a kind of discussion, “well, here’s the pros and 298 
here’s the cons and it’s somewhere in between” and it’s a grey, grey area discussion we can’t perfectly 299 
quantify. So our familiarity with that type of conversation might be greater [than the surgeons’]’ (MO3).  300 
Thus, the medical oncologists deployed legitimacy discourses to position themselves as 301 
competent and better suited for this work than their surgical colleagues (see Sanders and 302 
Harrison, 2008). Finally, the medical oncologists were clear about the clinical utility of the TFGT 303 
result for the treatment of their patients: 304 
To know the BRCA status of a patient … ‘determines the treatment’. The oncologists request an urgent 305 
result and, usually, they will get the result within 4 weeks. This is by mid-chemo, and the outcome is 306 
important because they can change the chemo regime, if necessary. If a patient comes back BRCA + then 307 
‘Carboplatin’ will be added into the chemotherapy. Therefore, knowing the BRCA status of the patient 308 
before neoadjuvant therapy is completed is absolutely vital for the care they are providing patients 309 
(interview notes MO2).  310 
Knowing the BRCA status of a patient is, therefore, crucial for providing appropriate 311 
oncological care and, consequently, there was strong interest among the medical oncologists to 312 
learn this information as soon as possible. Despite this logic, it was the case that medical 313 
oncologists may not, in fact, know their patient’s BRCA status at the time of commencing 314 
chemotherapeutic treatment. Consequently, mainstreaming the pathway presented the 315 
opportunity for the medical oncologists to gain control over the timing of testing for patients 316 
which would support them in their clinical practice. However, it should be noted here that 317 















oncologists expanding their jurisdiction, mainstreaming the pathway would still require the 319 
genetic team to interpret the results of TFGT because in this locally designed mainstreamed 320 
model, genetic results would come from the laboratory to the genetics team who would then 321 
report back to the clinician and patient. So, while the genetics team were instrumental in getting 322 
medical oncologists to take on the role of consenting and testing patients, it remained the case 323 
that they would maintain intellectual sovereignty over the task of interpreting lab results. This 324 
echoes with the findings of both Martin et al. (2009) and Miller et al. (2008), who similarly found 325 
that while roles and responsibilities shifted in response to the new technological possibilities of 326 
the genomics era, this devolution was not all encompassing, as competing visions of the future 327 
of genetics in medicine and medical practice were negotiated. Arguably, the negotiations about 328 
the mainstreamed care pathway at our field-site can be seen as a momentary opening up of inter-329 
professional boundaries, which was intended to facilitate the ensuing reinforcement (as opposed 330 
to de-territorialisation) of the genetics team’s realm of expertise.  331 
Contrary to the oncologists, all of the surgeons expressed reticence to expand their professional 332 
jurisdiction to include the consenting of patients for TFGT. Surgeons’ ambivalence appeared to 333 
be explicitly linked to their concerns about workload management, lack of certainty around 334 
clinical relevance, and the need to maintain a distinct professional jurisdiction. Indeed, while one 335 
of the surgeons noted that mainstreaming demanded ‘identifying who needs testing and getting it done as 336 
quickly and as efficiently as possible and sharing the pain of who does it’ (BS6), none of the surgeons 337 
suggested that they would be able, or willing, to participate in delivering the new pathway. As 338 
BS1 said, ‘we’re really in a clinic dealing with people with lumps and we’re looking to diagnose their lumps rather 339 
than do all the genetic screen’.  340 
It appeared that the surgeons’ ambivalence about mainstreaming might also have been 341 
influenced by a misunderstanding as to what this new care pathway would involve. Observations 342 















One of the surgeons interrupted the other and said that they would have to counsel the patient, rather 344 
than triaging and sending them on to genetics. This caused another to say ‘I thought clinical genetics were 345 
meant to counsel’, to which an oncologist said, no, they were moving towards a ‘mainstreamed’ service, 346 
‘like ovarian’. There was clearly some confusion regarding the proposed changes (Field-notes from 347 
breast MDM 14/03/2017).  348 
Unsure about what they were being asked to do, the surgeons seemed to resist the idea of 349 
mainstreaming, regarding it as too onerous - adding an unmanageable workload to their already 350 
over-stretched service:  351 
‘So, you know … if you look at what we are doing as clinicians you’re doing more and more on more 352 
and more patients. And if we’ve then got to prepare the patients for genetic testing, and the view of the … 353 
genetic counsellors is if you have set criteria of which you can test people then to speed it up we can actually 354 
take the blood and counsel the patients, and then send it off for testing. I’m not sure we can take on much 355 
more realistically.  I’ve got like five things open. I’ve got my clinic open. I’ve got my you know, my emails, 356 
my calendar open, I’m booking operation dates. I‘m-, some days I’m seeing 20 in a morning….’ (BS2).  357 
Like the orthopaedic surgeons in Norris’ (2001) study of occupational boundary maintenance in 358 
musculo-skeletal treatment, the legitimacy claims made by the breast surgeons about their 359 
position and jurisdictional boundaries were framed around concerns about capacity. There was, 360 
however, a further explanation for the surgeons’ lack of enthusiasm about the mainstreamed 361 
pilot, namely, they did not regard TFGT as integral to their practice of treating cancer. Instead, it 362 
appeared that the surgeons regarded genetic testing as primarily a means to prevent future cancers 363 
from occurring. In other words they did not see this new application of genetic testing as useful 364 
(Hedgecoe, 2008) in their day-to-day care of patients. In his study of the implementation and 365 
uptake of pharmacogenetic testing, Hedgecoe suggests that it is important to interrogate ‘how 366 
‘’useful’’ specific tests are in specific contexts, [in] a way that places the onus squarely back on 367 















emphasis on the usefulness of genetic testing and pharmacogenetics resonates somewhat with 369 
the responses from the surgeons in this study insofar as they were sceptical about the test’s 370 
clinical utility for their practice. Where our findings diverge from Hedgecoe, however, is our 371 
consideration of how the new technology of TFGT, in the context of wider policy and cultural 372 
shifts towards the mainstreaming of genomics, worked to force jurisdictional negotiations among 373 
study participants. Yet, while the surgeons questioned the utility of TFGT for their practice, they 374 
nevertheless recognised that mainstreaming BRCA testing would benefit patients:  375 
‘I just think it needs to become more part and parcel of breast cancer treatment, and it needs to become 376 
much more routine and we need to work out a way in which it’s easy for us to, easier, quick for it to be 377 
done by the right people, in a timely way’ (our emphasis BS6). 378 
Crucially, it seemed that the surgeons did not regard themselves as being the right people for the 379 
task and, in fact, it appeared that both the genetics team and medical oncologists were 380 
sympathetic to the surgeons’ position. As we have seen, medical oncologists regarded themselves 381 
as having more appropriate skills than the surgeons to take on consenting and testing while, as 382 
one member of the genetics team noted, ‘…if I had to put a fair interpretation, I think they’re [surgeons] 383 
very busy’ (CG4).  384 
On speciality champions as ‘boundary spanners’ 385 
Up to this point we have focused on the responses of surgeons and medical oncologists in 386 
relation to the proposal put forward by the genetics team to mainstream the breast care pathway. 387 
Referring to what Anteby et al (2016) call the ‘doing lens’ of occupational jurisdictional 388 
negotiations, we have seen the different ways in which these stakeholders have indicated their 389 
interest in, or ambivalence towards, the pilot.  The responses of medical oncologists and 390 
surgeons have been linked to considerations of expertise, relevance, and workload raised by 391 
participants. For example, as evidenced above, the enthusiasm expressed by the medical 392 















oncology (Hamburg and Collins 2010). Yet, there was something more in our participants’ 394 
accounts, namely, the interlinked consideration of the impact of professional disconnectedness 395 
constructed by virtue of the existing care pathway, and the role of speciality champions in 396 
facilitating cooperative communication. Our data suggest the negotiations that take place at times 397 
of pathway change can be conceptualised spatially, troubling established professional boundaries 398 
and hierarchies (Bleakley 2013). It was within this context of uncertainty at our field-site that 399 
specialty champions were viewed by some to be crucial in turning the pilot care pathway (a 400 
‘boundary object’) into a ‘boundary-object-in-use’ (Allen 2009), that is,  as acceptable to 401 
stakeholders and successfully implemented.  402 
Allen notes that care pathways are symbolic ‘boundary objects’, which span ‘several social worlds 403 
and fulfil a role in structuring relations between them’ (Allen 2009: 355).   Consequently, care 404 
pathways reify professional jurisdictions, and have the capacity to physically separate 405 
practitioners, as tasks are conducted in assigned spaces. In our study, the jurisdictional silos 406 
created by the standard care pathway were reinforced by the physical separateness of the breast 407 
unit from the genetics department, this physical space acting as a barrier to cooperation and 408 
mutual understanding. As one of the genetic counsellors reflected: 409 
‘It’s hard, because it would make quite a lot of sense to co-locate. Because if you bump into people in the 410 
tearoom that’s when you get to know them, isn’t it? And you work well together when you know more 411 
about each other and what you do, what constraints there are on what you’re doing and why you seem to 412 
be acting in a bizarre way. You know, you just get a better sense of what, where people are coming from’ 413 
(CG5).  414 
It was not only the genetics team who felt this way. BS2 also talked about the need for further 415 
integration across the specialities, noting that the genetics clinic is physically removed from the 416 















‘I think, in other centres I’ve worked in, the geneticists are more integrated into the team on the ground. 418 
Whereas genetics here are removed from us. Everything is done by correspondence. We never see 419 
any… the whites of anybody’s eyes’ (our emphasis BS2).  420 
Of particular interest, however, is that despite being located away from the genetics department, 421 
a collaborative cooperation was established between the genetic counsellors and medical 422 
oncologists. Our data provide insights into participants’ explanations for this which go beyond 423 
concerns of expertise, workload and clinical relevance to focus on the role of a specialty 424 
champion in medical oncology. As one of the genetics team members noted: 425 
‘I think the oncologists will but that’s just because of the experience with the ovarian and that somebody 426 
like [name]. I think [name] is likely to follow through on this, and [name] is interested. So there’s, I 427 
think those are, those are people that understand, they genuinely seem to want to do it’ (CG4).  428 
We suggest, thus, that the speciality champion might be viewed as a ‘boundary spanner’ – an 429 
individual whom, in promoting collaboration and overcoming the challenges of both physical 430 
separateness and communicative barriers which are reified in the standard pathway – is central in 431 
relation to ‘the emerging cross-boundary practices-in-the-making’ (Kislov 2018: 830). Put simply, 432 
the speciality champion as ‘boundary spanner’ facilitates the creation of a momentary dynamic 433 
communicative space wherein new roles and responsibilities could be negotiated.  While there is 434 
little mention of champions in the literature (Keshet et al 2013), in their role as ‘boundary 435 
spanners’ they can be understood as pathway facilitators, integral to the successful 436 
implementation of new pathways (Hunter and Segrott 2008; Harvey and Currie 2000). Certainly, 437 
in our research, we found that key actors appeared fundamental to the success of the 438 
mainstreaming of BRCA testing within gynaecology (Wright et al 2018) and also the 439 
implementation of the breast care pilot. Specialty champions might then be considered as 440 



















This study offers timely examination of the reconfiguration of professional jurisdictions amongst 446 
surgeons, medical oncologists and genetics team members in response to the implementation of 447 
a proposal to pilot a mainstreamed pathway for the delivery of TFGT to breast cancer patients at 448 
a regional hospital. While significant attention has been given to the relationship between new 449 
genetic technologies and individual (often female patient) responsibility (Arribas-Ayllon 2016), 450 
we have focused here on the relationship between genetics and professional responsibility, as 451 
innovative applications of technologies are integrated into clinical practice. As our findings 452 
demonstrate, this integration in different specialities results in the renegotiation of work 453 
territories and jurisdictional boundaries, which contribute to relatively scant research on the 454 
emergence of cooperative, generative occupational relations (in this case, between the medical 455 
oncologists and genetics team) in the context of jurisdictional negotiations (Anteby et al 2016). 456 
Drawing upon theories of professional boundary-making our data suggests that the introduction 457 
of TFGT elicits multiple responses in relation to shifting boundaries of expertise and practice: 458 
defending positions (surgeons); a willingness to expand the boundaries (oncologists) and; a desire 459 
to re-assign tasks and re-establish boundary of expertise and practice (genetics team).  460 
Crucially, our research offers an example of jurisdictional negotiations that are not hinged upon 461 
competition, encroachment and defence of territory – the common concerns of sociological 462 
studies of professions (see Zetka 2001). Rather, our findings offer a different, and intriguing, 463 
example of a profession (clinical genetics) willingly relinquishing tasks to others, and the 464 
response of surgeons (ambivalence, and maintenance of existing jurisdictions) and medical 465 















reassign a subset of their tasks, should not, however, be seen as professionally cavalier. Quite the 467 
contrary, in handing tasks to others, the genetics team were acting in what they saw as their, and 468 
their patients’, best interests - to re-establish clear boundaries around their jurisdiction, and re-469 
assert their expertise. The introduction of TFGT had made their jurisdiction unbounded. 470 
Relinquishing less-specialised tasks to others offered the genetics team the opportunity to return 471 
to clearer jurisdictional expertise. The actions on the part of the genetics team could, thus, be 472 
understood as an active ‘discarding of unwanted tasks to another provider’ of similar training 473 
(Nancarrow and Borthwick 2005: 905), a process which can result from mutually agreed transfer, 474 
or be stifled by conflict.  As we have seen in relation to our study, there was enthusiasm from the 475 
medical oncologists to expand their jurisdiction, linked to an understanding that this made 476 
pragmatic sense (Nancarrow and Borthwick), while the surgeons remained distant.  477 
 478 
In summary, our data suggest that the question of professional jurisdictions in relation to the 479 
delivery of genetics in medicine generally, and cancer care specifically, is not simply about turf 480 
battles (Miller et al. 2008). Instead, the question that should be asked is what genetic technologies 481 
can achieve in clinical practice (Miller et al. 2008; Hedgecoe 2008). As our study, and others’ 482 
(Hamburg and Collins 2010; Miller et al. 2008) have shown, oncology appears to be a specialism 483 
where the uptake of mainstreaming is welcomed, this almost certainly because medical 484 
oncologists regard the streamlining of genetic/genomic testing as a clear, practice-focused 485 
rationale, informed by the results of clinical trials.  486 
The making of an oncogenetic taskscape 487 
Thus far, this paper has presented the findings from our study pertaining to the views and 488 
experiences of healthcare practitioners in relation to a proposed, mainstreamed TFGT pathway 489 
for breast cancer patients at the field-site hospital. The data suggest our interviewees fall into two 490 















medical oncologists and the genetics team), versus those who did not (the surgeons). Ingold’s 492 
(1993) ‘taskscape’, a concept which refers to an ensemble of mutually interlocking tasks and 493 
related activities that forge dynamic connections- collaborations- between people, can be seen as 494 
a useful lens through which to interrogate the relationship between care pathway development 495 
and the professional jurisdictional negotiations at our field-site. Indeed, the design and 496 
implementation of the mainstreamed care pathway for breast cancer patients is an ongoing social 497 
process, which hinges upon the forging of productive and collaborative inter-professional 498 
relationships in order to successfully create and maintain this new pathway for care provision.  499 
Drawing on Ingold’s (1993) concept, we suggest that our findings might be understood as an 500 
‘oncogenetic taskscape in the making’. First, we refer to the oncogenetic taskscape as a way to 501 
conceptualise the dynamic social process of professional jurisdictional negotiations that were 502 
ongoing during our fieldwork. In these discussions, the genetics team members and medical 503 
oncologists were united in their opinion that TFGT was a diagnostic test and, therefore, should fall 504 
under the jurisdictional responsibility of the oncologists. This echoes somewhat the community 505 
of practice that espoused an oncogenetic vision of cancer care in Miller et al. (2008). Yet, our 506 
oncogenetic taskscape differs from the oncogenetic vision described by Miller et al. because in 507 
our study the medical oncologists had an enduring recognition of the genetics team’s expertise, 508 
most notably in relation to the interpretation of complex results (i.e. genetic variants of uncertain 509 
significance). Thus, the oncogenetic taskscape recognises that neither party see transferring the 510 
task of offering TFGT to oncology as challenging the genetics team’s expertise. Thus, while it 511 
has been suggested that the future of genetic medicine is in devolved, diasporic pathways, located 512 
in disease specific areas of care provision (Guttmacher, Jenkins and Uhlmann 2001), our study 513 
offers a different outlook. The oncogenetic taskscape emphasises the creation of an inter-514 
professional collaboration which, while seeing the transferal of certain tasks to disease specific 515 















genetics nevertheless maintains sovereignty over genetic expertise in the interpretation of 517 
complex results and concerns of the family.  518 
To our oncogenetic taskscape, we add ‘in the making’, and in so doing acknowledge Pinder et 519 
al’s (2005) assertion that the process of creating care pathways (the cultural cartography of which 520 
they write) must be regarded as a process that is ‘always in the making’ (2005: 776). We similarly 521 
emphasise ‘in the making’ to indicate that the negotiation of professional jurisdiction associated 522 
with the design of the new mainstreamed pathway is co-evolving, ongoing and, as such, 523 
unknown. Indeed, as Hunter and Segrott note in their review of the use of clinical pathways by 524 
nurses and midwives, despite their status as tools which map things out clearly, care pathways, in 525 
their implementation, often represent a ‘journey into the unknown’ for those involved (2008: 526 
623). Furthermore, the implementation of new technologies or, in this case, new applications of 527 
existing technologies, not only require adjustments to work routines, but also unfold ‘along a 528 
course that is a bit uncertain’ (Zetka 2001: 1512). Thus, we suggest that the ‘oncogenetic 529 
taskscape in the making’ represents, both, the collaborative space forged by medical oncologists 530 
and genetic team members who, buoyed by a shared understanding of the potential benefits of 531 
the new pathway, undertook the task of negotiating new jurisdictional boundaries, and the still 532 
uncertain character of the pathway, which is yet to transition from pilot phase to official 533 
pathway.  534 
Limitations  535 
There are limitations to this study. In the first instance, it captured only the moments of planning 536 
and early implementation of the mainstreamed care pathway in breast cancer care at our field-site 537 
and so does not speak to the experiences of clinicians and genetics team members as they put 538 
their plans into practice, nor does it assess the success, or shortcomings, of the pilot. Certainly, 539 
while not viewing substitution as a risk to their professional expertise, it is nevertheless the case 540 















be for the genetics team. Furthermore, the findings are limited to one location and a particular 542 
group of participants. Despite these shortcomings, this study offers an in-depth, contextual 543 
examination of the process of change to professional jurisdictions that accompanies the 544 
introduction of new technologies and, thus, provides a clear example of how the growing 545 
impetus on moving genomics in clinical practice impacts on inter-professional relationships and 546 
the provision of care.   547 
Conclusions  548 
This study offers a detailed analysis of the locally negotiated process to implement a 549 
mainstreamed TFGT pathway at our field-site. By focusing on professionals’ experiences as they 550 
negotiate the possibilities of a new, mainstreamed pathway for patients with breast cancer and 551 
their respective roles within this, we found that members of different professional groups 552 
differed in terms of their willingness to expand their jurisdiction and maintain professional 553 
boundaries. Reasons for, either, support for the pilot or lack of enthusiasm linked to issues of 554 
perceived clinical relevance of the technology for their clinical practice, and their beliefs about 555 
acceptable jurisdictional parameters. Our data suggests that the design and implementation of 556 
new pathways in patient care is a processual and dynamic social arrangement, which is on-going, 557 
fluid and uncertain. Capturing a period of time wherein negotiations for the pilot were underway, 558 
it remains to be seen how this new pathway, and the continued integration of new genetic 559 
technologies into standard care more generally, will impact on professional jurisdictional 560 
boundaries, inter-professional communications and patient care.  In closing, we propose that the 561 
oncogenetic taskscape in the making is a helpful concept that not only captures ongoing negotiations 562 
of the pathway, and the inter-professional dynamics of change-making within the context of the 563 
integration of mainstreamed TFGT into the breast cancer care pathway, but also is illustrative of 564 
the locally mediated, dynamic jurisdictional negotiations which are likely to arise as a 565 
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REFERRAL TO CLINICAL GENETICS  
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PATIENTS AND CLINICIANS RECEIVE G NETIC RESULT FROM CLINICAL GENETICS  
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A micro-level examination of clinicians’ work assembling an ‘oncogenetic taskscape’.  
Mainstreaming genomic testing requires changes to professional jurisdictions. 
Technology’s clinical relevance informs clinicians’ acceptance of mainstreaming. 
Clinical implementation of new technology requires inter-professional collaboration.  
 
